

## AHCI Grand Rounds

**Title:** AHCI Grand Rounds Recorded 7-15-2026: Management of Bladder Cancer

**Recorded Date:** July 15, 2026

**Location:** Online

**Faculty:**

Grant Wintheiser, MD

Medical Oncologist

Allina Health Cancer Institute

**OVERVIEW/PURPOSE STATEMENT:**

Recorded Presentation from AHCI Grand Rounds. Expires 7/14/2027. Duration = 48 minutes

Dr. Grant Wintheiser discusses how the management of muscle-invasive bladder cancer (MIBC) has changed dramatically after decades of limited therapeutic advances, evolving from a standard approach of neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy and selective adjuvant nivolumab toward more effective perioperative strategies. He shares that historically, cisplatin-based regimens improved overall survival by approximately 510% and achieved pathologic complete response (pCR) rates of 2540%, but recurrence remained common, prompting interest in biomarkers such as circulating tumor DNA (ctDNA), which has emerged as a powerful predictor of recurrence risk and survival. He updates on how recent phase III trials have established perioperative enfortumab vedotin plus pembrolizumab (EV-Pembro) as a new standard of care for both cisplatin-eligible and cisplatin-ineligible patients, improving pCR rates to approximately 5560% while significantly enhancing event-free and overall survival. At the same time, bladder-preservation approaches, including trimodality therapy and investigational active surveillance strategies, are gaining interest, although ctDNA alone is insufficient to detect residual bladder disease and may need to be combined with urinary tumor DNA, cystoscopy, and imaging for optimal patient selection. He stresses the importance of clinicians being prepared to monitor and manage EV-related toxicities, particularly rash, peripheral neuropathy, ocular disorders, and hyperglycemia, while ongoing studies seek to define the ideal duration of therapy and identify patients who may safely avoid cystectomy.

**OVERALL OBJECTIVES**

At the completion of this activity, the participants should better be able to:

- 1 Differentiate historical and current standards of care for muscle invasive bladder cancer (MIBC), including the role of cisplatin based neoadjuvant chemotherapy, radical cystectomy, adjuvant immunotherapy, and perioperative enfortumab vedotin plus pembrolizumab (EVPembro).
- 2 Evaluate patient specific factors, including cisplatin eligibility, disease stage, comorbidities, and pathologic risk features, to select evidence based treatment approaches for patients with muscle invasive bladder cancer.
- 3 Interpret key outcomes from recent practicechanging clinical trials (EV302, EV303, EV304, CheckMate 274, and ctDNAguided studies) and apply these findings to contemporary treatment decisionmaking in MIBC.
- 4 Assess the clinical utility and limitations of circulating tumor DNA (ctDNA) and urinary tumor DNA as prognostic and diseasemonitoring tools for predicting recurrence risk, guiding adjuvant therapy considerations, and informing bladderpreservation strategies.

# Office of Accreditation

Continuing Medical Education (CME)



5 Develop individualized management plans that incorporate bladderpreservation approaches, including trimodality therapy and emerging active surveillance strategies, while recognizing appropriate patient selection criteria and management of common enfortumab vedotin-associated toxicities.

## ACCREDITATION AND DESIGNATION STATEMENT:

Allina Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The individual is responsible for determining whether this activity meets the requirements for acceptable continuing education for their discipline. In addition, you may be required to provide proof of attendance to the board upon request such as certificate, handout, agenda, etc. You should claim only those hours spent in the educational program.

**Physicians:** Allina Health designates this Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Non-Physicians:** Allina Health designates this Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>.

**Nurses:** Allina Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Allina Health designates this live activity for 1.00 contact hours.

## DISCLOSURE POLICY:

Allina Health, Office of Accreditation intends to provide balance, independence, objectivity, and scientific rigor in all of its educational activities. The ACCME defines an ineligible company as "any entity" whose primary business is producing, marketing, re-selling, or distributing health care products/services used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company. All faculty and planners participating in the CME activity are required to disclose to the audience any relevant financial relationships with ineligible companies that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended, and all relevant financial relationships will go through a mitigation process.

## FACULTY & PLANNER DISCLOSURES:

Allina Health, Office of Accreditation Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

| Name of individual                             | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|------------------------------------------------|-------------------------------|-----------------------------------------------------------|
| Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN | Nurse Planner                 | Nothing to disclose - 07/09/2026                          |
| Lisa Mackeben, MSN                             | Peer Reviewer                 | Nothing to disclose - 12/16/2025                          |
| Grant Wintheiser, MD                           | Faculty                       | Nothing to disclose - 07/07/2026                          |

**PLEASE SAVE - SERVES AS YOUR CERTIFICATE OF ATTENDANCE.**